Innovator. Advocate.Together with patients, on a mission to advance transformative treatments for people living with serious cardiometabolic diseases.
At Akcea, we’re on a mission to transform the treatment of unaddressed or under-addressed lipid-based cardiometabolic disorders with leading-edge, RNA-targeted medicines. Whether you’re a patient living with a serious lipid disorder, or a physician whose patient desperately needs a therapy, we know you’re counting on us, and it fuels our unwavering commitment to be a partner to the community through innovation.
Cardiometabolic Lipid Disorders
There is a significant need for new therapies targeting the protein and lipid risk factors associated with these serious, complex diseases
Volanesorsen – Our Lead Program for FCS and FPL
Phase 3 studies are underway to treat two rare, genetically defined lipid disorders that severely impact the lives of those affected
NewsView all News
Learning about familial chylomicronemia syndrome (FCS)
FCS is a rare, genetic disease caused by an enzyme deficiency that leads to the buildup of chylomicrons and a high risk of life-threatening pancreatitisVisit FCSFocus.com